APA
Kollef M. H., Nováček M., Kivistik Ü., Réa-Neto Á., Shime N., Martin-Loeches I., Timsit J., Wunderink R. G., Bruno C. J., Huntington J. A., Lin G., Yu B., Butterton J. R. & Rhee E. G. (20200615). Ceftolozane-tazobactam versus meropenem for treatment of nosocomial pneumonia (ASPECT-NP): a randomised, controlled, double-blind, phase 3, non-inferiority trial. : The Lancet. Infectious diseases.
Chicago
Kollef Marin H, Nováček Martin, Kivistik Ülo, Réa-Neto Álvaro, Shime Nobuaki, Martin-Loeches Ignacio, Timsit Jean-François, Wunderink Richard G, Bruno Christopher J, Huntington Jennifer A, Lin Gina, Yu Brian, Butterton Joan R and Rhee Elizabeth G. 20200615. Ceftolozane-tazobactam versus meropenem for treatment of nosocomial pneumonia (ASPECT-NP): a randomised, controlled, double-blind, phase 3, non-inferiority trial. : The Lancet. Infectious diseases.
Harvard
Kollef M. H., Nováček M., Kivistik Ü., Réa-Neto Á., Shime N., Martin-Loeches I., Timsit J., Wunderink R. G., Bruno C. J., Huntington J. A., Lin G., Yu B., Butterton J. R. and Rhee E. G. (20200615). Ceftolozane-tazobactam versus meropenem for treatment of nosocomial pneumonia (ASPECT-NP): a randomised, controlled, double-blind, phase 3, non-inferiority trial. : The Lancet. Infectious diseases.
MLA
Kollef Marin H, Nováček Martin, Kivistik Ülo, Réa-Neto Álvaro, Shime Nobuaki, Martin-Loeches Ignacio, Timsit Jean-François, Wunderink Richard G, Bruno Christopher J, Huntington Jennifer A, Lin Gina, Yu Brian, Butterton Joan R and Rhee Elizabeth G. Ceftolozane-tazobactam versus meropenem for treatment of nosocomial pneumonia (ASPECT-NP): a randomised, controlled, double-blind, phase 3, non-inferiority trial. : The Lancet. Infectious diseases. 20200615.